IQVIA Holdings Inc. $IQV Shares Sold by Cullen Investment Group LTD.

Cullen Investment Group LTD. lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 13.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,941 shares of the medical research company’s stock after selling 3,199 shares during the period. Cullen Investment Group LTD.’s holdings in IQVIA were worth $5,076,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the business. Physician Wealth Advisors Inc. lifted its stake in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares during the period. Westside Investment Management Inc. increased its stake in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares during the period. Measured Wealth Private Client Group LLC purchased a new position in shares of IQVIA during the third quarter worth $30,000. Atlantic Union Bankshares Corp acquired a new position in IQVIA during the third quarter valued at $36,000. Finally, Root Financial Partners LLC acquired a new position in IQVIA during the third quarter valued at $43,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on IQV. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Truist Financial lowered their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Morgan Stanley set a $240.00 target price on IQVIA in a report on Wednesday, February 11th. Evercore reissued an “outperform” rating and issued a $225.00 price target on shares of IQVIA in a report on Thursday, February 5th. Finally, UBS Group lowered their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Buy” and an average price target of $229.13.

IQVIA Trading Down 0.3%

IQV stock opened at $165.54 on Thursday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. The firm has a market cap of $28.09 billion, a P/E ratio of 21.06, a PEG ratio of 1.60 and a beta of 1.39. The company’s 50-day simple moving average is $189.63 and its 200-day simple moving average is $205.63.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.IQVIA’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.